Author: Editor

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jonathan Friedberg argues that young paitnts with mantle cell lymphoma (MCL) should not be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Brad S. Kahl argues that young patients with mantle cell lymphoma (MCL) should be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Anas Younas discusses immune checkpoint inhibitors in lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard I. Fisher argues that R-CHOP should be utilized to treat patients with ABC-type diffuce large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Pierluigi Porcu argues that allogeneic stem cell transplant is the best approach for relapsed T cell lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Rafael Bejar discusses the promises and pitfalls in using molecular testing in the diagnosis of myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents should be used with caution in lower-risk patients with myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the management of chronic myelomonocytic leukemia (CMML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben A. Mesa discusses combination therapy with JAK2 inhibitors in the treatment of myeloproliferative neoplasms (MPN). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Sarah Nikiforow discusses the diagnosis and management of hemophagocytic lymphohistiocytosis (HLH). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Kenneth A. Bauer discusses the reversal of newer anticoagulants. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the diagnosis and management of atypical chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Racdich discusses practical advices for the molecular monitoring of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point tyrosine kinase inhibitors can be stopped in the treatment of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment for chronic lymphocytic leukemia (CLL) patients with a 17p deletion is the use of a novel agent. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jacqueline Barrientos argues that ibrutinib is the optimal treatment for chronic lymphocytic leukemia (CLL) patiens with a 17p deletion. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Timothy Call discusses the clinical considerations for the use of oral targeted therapies in chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and MRD negativity is no longer required for treatment of CLL in the era of novel agents. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that the best multiple myeloma salvage therapy is KRD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the best multiple myeloma salvage therapy is novel therapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that upfront transplant should no longer be considered a standard of care in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky argues that high risk myeloma should not be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that high risk myeloma should be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the standard induction regimen for myeloma is RVD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky discusses the use of monoclonal antibodies for the treatment of multiple myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses novel approaches to trial design in the era of molecular subtyping. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Karen T. Brown argues that ablation is the optimal treatment of localized hepatocellular carcinoma (HCC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that the optimal treatment of localized hepatocellular carcinoma (HCC) is either resection or transplant. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that chemotherapy alone is the preferred treatment for borderline, resectable pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt argues that epirubicin and other anthracyclines still have a role to play in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. David H. Ilson argues that epirubicin and other anthracyclines no longer have a place in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that the optimal pre-operative therapy for esophagus and GE junction cancers is chemotherapy alone. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses the molecular subtyping/profiling of upper-GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016” Dr. James C. Yao argues that bevacizumab cannot treat pancreatic neuroendocrine tumors (pNET). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Diane Reidy-Lagunes argues that everolimus does not have a role in the treatment of carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. James C. Yao argues that everolimus has a role in carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Mark Andrew Dickson discusses the management of GIST tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael J. Hall discusses genetics in gastrointestinal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Luis A. Diaz discusses the use of liquid biopsies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses novel therapies for gastrointestinal malignancies beyond immunotherapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that biomarkers beyond MSI cannot direct immunotherapy in gastrointestinal malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt discusses inflammation in colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that TAS-102 followed by regorafenib is the preferred salvage therapy for metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC) should be treated with a chemo doublet with EGFR inhibitor. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.